Nu Skin Enterprises Q2 2025 Earnings Report

Nu Skin Enterprises EPS Results

• Actual EPS: $0.43
• Consensus EPS: $0.25
• Beat/Miss: Beat by +$0.18
• One Year Ago EPS: N/A

Nu Skin Enterprises Revenue Results

• Actual Revenue: $386.14 million
• Expected Revenue: $376.68 million
• Beat/Miss: Beat by +$9.46 million
• YoY Revenue Growth: N/A

Nu Skin Enterprises Announcement Details

• Quarter: Q2 2025
• Date: 8/7/2025
• Time: After Market Closes
• Conference Call Date: Thursday, August 7, 2025
• Conference Call Time: 5:00PM ET

Nu Skin Enterprises (NYSE:NUS), together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

Nu Skin Enterprises Q2 2025 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: We delivered Q2 revenue of $386.1 million at the high end of guidance and reported EPS of $0.43, well above the $0.20–$0.30 forecast.
• Neutral Sentiment: Latin America grew over 100% year-over-year while North America faced declines and other regions showed mixed results.
• Positive Sentiment: Nu Skin plans a limited Q4 rollout of Prism.io, its AI-driven wellness platform, with broader leader and consumer launches in 2026.
• Positive Sentiment: The developing market strategy advances with a Q4 premarket in India for qualified leaders and a mid-2026 formal launch of the SeraNu masstige brand.
• Positive Sentiment: Operational improvements drove an 8% Q2 operating margin, and the company became net cash positive with $264 million in cash for increased financial flexibility.

Presentation

[Operator]

Good day, and thank you for standing by. Welcome to the Q2 twenty twenty five Nu Skin Enterprises Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.

[Operator]

You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, BG Hunt, Vice President of Treasury and Investor Relations. Please go ahead.

[B.G. Hunt, VP - Treasurer, IR & Admin Services at Nu Skin Enterprises]

Thanks, James, and good afternoon, everyone. I'm joined by Ryan Napierski, President and CEO and James D. Thomas, CFO. We're excited to share Nu Skin's results from 2025. Before I turn the time over to Ryan, let me point out that on today's call, comments will be made that include forward looking statements.

[B.G. Hunt, VP - Treasurer, IR & Admin Services at Nu Skin Enterprises]

These statements involve important risks and uncertainties, and actual results may differ materially from those discussed or anticipated. Please refer to today's earnings release and our SEC filings for a complete discussion on these risks. Also during the call, certain financial numbers may be discussed that differ from comparable numbers obtained in our financial statements. We believe these non GAAP numbers assist in comparing period to period results in a more consistent manner. Please refer to our investor website, ir.nuskin.com, for any required reconciliation of these non GAAP numbers. And with that, I'd like to now turn the call over to Ryan.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

Thanks, B. G. Thanks, everyone, for joining the call. We spent some time this past quarter with our amazing and talented top leaders in our annual team lead incentive trip in Greece where we aligned around our vision, strategy and plans for our next big opportunities, which I'll get to in just a moment.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

But before I get to the strategy, I'll begin with an overview of our Q2 performance, then provide an update on our key strategic priorities for the remainder of 2025 as we continue pursuing our mission of being a global force for good by empowering people to look, feel and live better lives. I'm pleased to report that we delivered revenue at the high end of our guidance range and significantly exceeded our earnings per share forecast for the second quarter. We achieved revenue of $386,100,000 More notably, we delivered earnings per share of $0.43 well above our guidance range of zero two zero dollars to $0.30 This strong earnings performance reflects our disciplined approach to cost management and operational efficiency improvements that we've been implementing across the organization. As we review our reporting segments, we're seeing encouraging signs in several parts of the business as we navigate the macro environmental uncertainties impacting consumers around the world. We continue to drive strong year over year growth in Latin America as our developing market strategy takes hold in the region.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

This was offset by declines in North America, which has faced increasing macro pressures for the on the business. Japan reported growth in the quarter and continues to benefit from a strong subscription based wellness business. While revenue in South Korea and China was down due to persistent economic challenges, we're seeing signs of sequential improvement. We experienced growth in The Pacific, while the rest of Southeast Asia remained sluggish. Europe and Africa also experienced improving trends in customer and new sales leader engagement with our enhanced sales performance plan.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

And our Rise segments performed well with manufacturing reporting 17% up year over year in the quarter. Now let me update you on our strategic priorities for 2025 as we made significant progress in preparing our sales leaders for these next opportunities. First, we're making good progress in bringing to market our next big innovation prism.io, our truly intelligent wellness platform. As I mentioned in Q1, prism.io was built upon more than twenty years of collective scientific research and development and our extensive antioxidant database that contains more than 20,000,000 scans from 10,000,000 participants across more than 50 countries. By utilizing AI capabilities to interpret this data through our own proprietary new intelligent platform, we'll be able to provide our customers with truly intelligent healthy lifestyle insights as well as personalized product recommendations to improve their antioxidant score and support their wellness journey.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

In just fifteen seconds, this palm sized device will accurately and non invasively measure carotenoid levels in the skin via the fingertip. As we educate consumers on four primary dimensions of health diet, fitness, oxidative stress, and supplementation their PRISM IO score can provide insights to motivate them to implement lifestyle changes aimed at improving their overall health span. We'll begin rolling out Prism IO in limited quantities for qualified sales leaders during the fourth quarter of this year, followed by broader leader launches around the globe in the 2026 and consumer launches anticipated to the back half of the year. The Prism. Launch will be accompanied by enhanced and expanded line of geographically customized LifePack product solutions as well as other targeted wellness products via our subscription based retention model.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

We will be reformulating our leading line of nutritional supplements, leveraging the latest metadata and scientific research to meet geographic dietary needs at various pricing tiers. For example, studies show that vitamin E is often underconsumed in many parts of the world, which can negatively affect immune and cardiovascular health. Adjusting vitamin E levels for these areas provides customized product solutions to better meet the needs of diverse consumer segments around the world. As consumers are growing increasingly more conscientious about their overall well-being, we're excited about the potential impact of prism.io and our revolutionary intelligent wellness platform. And with our unique ability to provide customized subscription based product solutions that support one's overall health and well-being, we are uniquely positioned to play in this rapidly growing wellness movement.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

Our second key priority is our developing market strategy, which continues to deliver remarkable results in Latin America, which reported up more than 100% year over year in revenue, customers and sales leaders. Nu Skin has historically been known for our premium market positioning in the beauty and wellness space. And as we envision a more expansive future for our company, it is imperative that we broaden our positioning to appeal to emerging segments in both existing and new markets. We continue to learn and gain insights that help us expand this strategy into other markets, including India, which represents an enormous opportunity given the 1,400,000,000 population and rapidly growing beauty and wellness industries. As we prepare for India, we're following this simplified and scalable business model, including a localized product portfolio containing a new masstige brand called SeraNu that is priced for India's growing middle class.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

This targeted product offering combined with a refined compensation plan and a digital first operating infrastructure will enable a more focused and scalable path to growth for this emerging market. We're on track with our plans in India for a Q4 premarket opening for qualified India eligible sales leaders and are building towards a formal launch anticipated in mid-twenty twenty six. We remain excited about the prospects for India and our other developing markets, which we anticipate will become a much larger portion of our revenue moving forward. And thirdly, we're pleased to see overall margin expansion through Project Accelerate, our ongoing initiative to improve operational efficiencies to strengthen our bottom line. We're focused on three key drivers: improving gross margin in the core Nu Skin business to 78% through product portfolio optimization selling expense alignment to better reward growth in our sales force and G and A prudence around the globe.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

Overall, our efforts led to significant improvements in our Q2 operating margin to 8%. We have also strengthened our balance sheet to become a cash to debt positive, which provides us with greater flexibility amid market fluctuations and an improved ability to invest in growth initiatives and return value to shareholders. One last point I'd like to mention is about RISE, our innovation incubator. As we experienced with our recently transacted Mavly business, which generated approximately $200,000,000 in value to the balance sheet, Rise plays a strategically significant role for our enterprise. Notably, Rise manufacturing, which grew 17% year over year, enables us to gain speed to market for new cutting edge beauty and wellness innovations.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

For example, our US business recently introduced mSmart, a drink mix in that helps support a healthy blood glucose response after meals and brought it to market in less than two months. Another Rise business, LifeDNA, a genetic wellness assessment business continues to perform ahead of expectations and we anticipate will support our broader intelligent wellness platform vision in the future. So with that, I'll turn the time over to James, who will provide more financial details, including our updated guidance for the remainder of 2025. James?

[James Thomas, EVP & CFO at Nu Skin Enterprises]

Thank you, Ryan. Good afternoon and thank you for joining us today for our Q2 earnings call. I'm pleased to provide an overview of our performance for the second quarter of the year, including key highlights, challenges and our outlook for the rest of 2025. As always, I'll walk through the financial results, touch on some key business dynamics, discuss our outlook for Q3 and the rest of the year, as well as provide an update on how we're navigating the current macroeconomic environment. Turning to our financial results for the quarter, I'm pleased to report solid performance in several key areas.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

For the second quarter, we delivered revenue near the top end of the range at $386,000,000 with neutral foreign currency impact. Earnings per share came in at $0.43 This surpassed our guidance by $0.13 and demonstrated significant improvement over the prior year $0.21 adjusted earnings per share due to our cost efficiency efforts deployed over the last two years. Our Q2 gross margin was 68.8% compared to 70% in the prior year, primarily due to the revenue mix between RISE entities and the Nu Skin core following the sale of Maisley. Within our core Nu Skin business, gross margin was 77.5%, up 140 basis points from the prior year, resulting in four quarters of sequential adjusted gross margin improvement. We're continuing to see the benefits of our portfolio optimization and operational refinement efforts.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

Selling expense as a percentage of revenue was 33.2% for the quarter, a decline from the prior year, primarily reflecting the impact of the Mabry sell on the overall revenue mix between our core Nu Skin business and Rise. Within the core Nu Skin segment, selling expense was 40%, down from 42.2% in the prior year. The decline was largely driven by lower sales performance in The U. S, China and Southeast Asia Pacific markets compared to the prior year. For the core, we anticipate selling expense to remain around 40% as the enhanced compensation plan continues to gain adoption.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

General and administrative expenses were down $11,200,000 compared to 2024, reflecting cost reduction efforts in labor and a migration to a shared service model for technology. It did increase on a percentage basis due to the overall declines in revenue. Operating margin for the quarter was 8%, up two sixty basis points from adjusted operating margin of 5.4% in the prior year due to our disciplined approach to operational efficiencies. Improving our operating margin remains a long term priority, which positions us to reinvest in the business through growth initiatives like Prism IO and new market expansion into India. We will remain disciplined and adaptable, especially when navigating the continued top line pressures and evolving market conditions and are very pleased with our operating income results year to date.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

I'd now like to turn to our balance sheet and liquidity position. We generated strong cash flow from operations in the quarter of $35,800,000 which enabled us to achieve our goal of becoming net cash positive ahead of schedule, the first time we've been in this position in more than four years. This net cash position provides us with strong financial flexibility, enabling us to navigate economic uncertainties more confidently, invest strategically in growth and return value to shareholders. We ended the quarter with $264,000,000 in cash. In line with our capital allocation strategy, we returned approximately $3,000,000 to shareholders in the form of a dividend.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

We did not repurchase any stock and have $157,400,000 remaining under our current share repurchase authorization. Looking ahead to the remainder of 2025, we're encouraged with the performance of the business through the second quarter. At the same time, we remain mindful of ongoing global uncertainties, including potential tariff impacts and evolving geopolitical conditions. Given these factors and continued uncertainty around consumer durability in our key markets, we're taking a disciplined and measured approach by narrowing our revenue outlook for the 2025 and increasing our earnings per share as we've proven our ability to deliver profitability, notwithstanding market headwinds and pressures on the business. We project third quarter revenue between $360,000,000 and $390,000,000 factoring in an expected foreign currency headwind of approximately 1%.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

Q3 earnings per share is anticipated to be in the range of $0.25 to $0.35 For 2025, we project revenue of $1,480,000,000 to $1,550,000,000 and earnings per share of $3.05 to $3.25 with adjusted earnings per share of $1.15 to $1.35 To conclude, we are pleased with our Q2 performance and continue to stay focused on driving our strategy forward despite ongoing global challenges. We remain confident in our ability to adapt and are committed to driving operational performance, managing costs, accelerating growth in key regions and maintaining a strong financial position. We look forward to updating you on our progress as we move through the 2025. And with that, operator, we'll now open up the call for questions.

[Operator]

Thank you. At this time, we will conduct the question and answer session. As a reminder, to ask a question, you will need to press 11 on your telephone and wait for your name to be announced. Our Our first question comes from the line of Dave storms from Stonegate. Dave, your line is now open.

[Dave Storms, Director - Equity Research at Stonegate Capital Partners]

Good evening and appreciate you taking my questions. Just want to start at the top here maybe with maybe just some thoughts around the puts and takes on your guidance. Great to see you guys narrow that range, but are there any initiatives or geographies that can maybe have an outsized impact that would put you on the higher end or lower end of that guidance?

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

Hey, Dave. Yeah. Just maybe I'll I'll share my thoughts, and then, obviously, James James can dive into a little bit better. But I think as as I mentioned through first half performance, you know, we continue to see Latin America, you know, overperforming expectations, a little bit offset through North America, which is a key market, you know, we're working to to improve there. You know, there again, puts and takes, as you said, it's Korea and China.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

Korea, we're seeing improving trends there. China's always, you know, a big question mark, especially with the macro, you know, uncertainties or uncertainties there, the economically and just geopolitically. So those are probably for me, the ones that are are are, like, top of mind would be those, you know, North America, China, Korea, whereas Europe, you know, Southeast Asia, and Japan and LatAm, I think are going to do better. But James, any additional color from

[James Thomas, EVP & CFO at Nu Skin Enterprises]

you No, as we look across the landscape, across the first two quarters of the year, there was a lot of shifts between geographies and the performance between the outcomes of our reported numbers through Q2. When we looked in the back half and we're forecasting out forward, Ryan touched on the ones where we see we've rolled through that over performance and then has also adjusted those other markets that have underperformed through the first half and looked at the energy maps and the programs that we have running in each of those regions. He touched on the highlights for us. Latin America continues to perform well. Japan continues to hold steady. And the other markets and regions we're looking forward to our Q4 launch of our Prism IO, as well as our getting ready and staging for the opening of India.

[Dave Storms, Director - Equity Research at Stonegate Capital Partners]

That's great color. I appreciate that. And then maybe just double clicking on the shrink seen in Latin America there. Are you able to highlight what's really working there and how much runway is left? Does Prism IO turn into is that pouring gas on the fire for Latin America?

[Dave Storms, Director - Equity Research at Stonegate Capital Partners]

Just kind of how you see that playing out in the near term?

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

Yeah. Yeah. Latin America has been an interesting journey for obviously, at the macro level, it's always been a region that has enormous potential in direct selling, but but for us has maybe been underrepresented. What we're pleased with there, we took a different approach there about two years ago, aligning with our leaders there around how we would simplify the model to really get a focus that would enable us to scale more profitably. And what we ended up finding out is the more we focused and simplified the model from an operational efficiency perspective, the the better the Salesforce aligned and focused.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

And so to true extent, less was more. And from there, that that was born kind of a three pronged strategy from the, from the product side, the business model side, and then the operational side. So at the product level, really retuning the the portfolio to hit at the right price points with a good retail profit, you know, from a sales leader perspective. So working through margins there, and and and that was important. On the business model side, as I mentioned, it's critical in those markets that there's a healthy and reliable retail profit that's made to the seller in addition to the incentives that we align around growing the channel.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

And so striking the right balance between that selling and referring together with our new sales performance plan is working really well. And then that last, you know, prong of of scalable, infrastructure there. So really focusing much more on the the the technical and technology based support rather than, you know, hard cost infrastructure has proven to to be helpful there, being able to get to, you know, the needs of the consumers and affiliates down there. So, you know, I think those are the those are really the elements of when we talk about the developing market strategy. Even in India, same three types of elements will be focused on the portfolio, the business model, and and the, the flexible digital first infrastructure.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

Prism, I think, will be a a an additional help there. Latin America historically has been a beauty origin market. You know, the majority of our business down there is that, but we have some some good nutritional products, like our collagen line down there that kind of spans the two. Our sales leaders are really excited about Prism and think there's a great opportunity moving forward with this expanded LifePack line, which is our premium nutritional supplement that works really hand in hand with Prism. And we have a new formula called LifePack Elements that we'll be introducing down there next year that that we anticipate will will further, you know, further strengthen the the the offering down there.

[Dave Storms, Director - Equity Research at Stonegate Capital Partners]

That's great. I I really appreciate that. Turning to, you know, at the consolidated level, the cost optimization that you've been kind of driving here, it seems to really be making some strong progress. When you're thinking about it going forward, how many levers do you still see to pull there? Is there any low hanging fruit that could continue to drive margin improvement year over year like we saw this quarter?

[James Thomas, EVP & CFO at Nu Skin Enterprises]

Yeah, I'll take that question, Dave. For us, we talked about earlier about four consecutive quarters of sequential growth in gross margin. That is the result of cumulative efforts across the last two years mainly and working through the inventory and the turns to get that flow through our cost of sales. So the lower overhead to roll through, we still believe that there's still opportunity there as we've lowered our inventory levels and managed that to be really in line with our overall revenue. Selling expense, we continue to optimize for us.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

That's something that helps the field and generates the top line. And so we're really focused on spending efficiently where we can to make sure that we're optimizing performance. And then G and A, we're going to continue to focus on our operational footprint like the developing market strategies that Ryan talked about in Latin America. We're looking across the scope of all of our markets and continue to look and find opportunities where we can use technology in place of physical presence or labor and continue to find opportunities where we can deliver more dollars to the bottom line. So we're going to continue our efforts and we feel confident in our ability to navigate our forward.

[Dave Storms, Director - Equity Research at Stonegate Capital Partners]

That's great. I really appreciate that commentary. Maybe just one more for me. You ended the quarter with a strong balance sheet, and you mentioned that it gives you a lot of flexibility. Just if you could help us maybe prioritize what your capital allocation priorities are going be in the back half of the year, given that flexibility?

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

Yeah. And maybe I could I'll have James kind of go into the detail on capital allocation. But I mean, obviously, for us, investing in growth of the business is critical and kind of doubling down on our two growth opportunities, Dave, for us that are always front and center. First from an innovation standpoint, Prism IO, as we're building upon the the extensive database that we've created over the last twenty years, to to now take that forward, in a new device that is really, you know, literally can can fit in in in anyone's pocket anywhere. This this device coupled with our our, database, extensive database, and then the app, the intelligent wellness app coming along is a major for us, it's a major focus and source of investment, as we lead out into this this new world.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

And then, of course, leading into developing markets, again, we have a scalable model. We're taking a very different approach, digital first there. So we're not talking about, you know, massive fixed cost infrastructure investments. Rather, we're we're we're really building it out to to be scalable. And so as we go into India, that's a priority and making certain that we're really allocating investment need or investment into growth first.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

But James, maybe you can talk more about capital allocation.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

Yeah. Our capital allocation strategy has been consistent. We fund the business. We look for opportunities where we can find the growth, Ryan mentioned. Right now, Prism IO, India, and then other several initiatives inside the business we're heavily funding.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

The second one is making sure that we're able to service our debt, that we can manage our obligations going forward with where we're in a really healthy position. And the third is to continue to pay a strong dividend, return value to shareholders through both our dividend and then when opportunity permits to be able to be in the market to repurchase shares. And so that's really what we have when we're looking forward. And we also look for other opportunities where we can take advantage of a potential opportunity that may arise to go after growth.

[Dave Storms, Director - Equity Research at Stonegate Capital Partners]

That's great. Thank you for taking my questions and good luck in 3Q.

[James Thomas, EVP & CFO at Nu Skin Enterprises]

Thanks, Dave.

[Operator]

Thank you. I am showing no further questions at this time. I would like to turn it back to Ryan Napiercey for closing remarks.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

Well, we really appreciate everyone joining the call. If you have additional questions, please reach out to BG, James, myself to answer those. We're very, very excited about the future as it's unfolding. We were pleased with our first half results and are now very focused on second half in preparations for 2026. We're going to be driving these three priorities across the business of accelerating innovation with prism.io and our intelligent wellness platform, our strengthening our core business with developing and emerging markets beginning with India, and then driving operational performance and efficiency, all with an end, end game of of strengthening shareholder value as we provide greater opportunities for our empowered Salesforce affiliates and and and powerful leaders around the world where we provide them opportunities to grow and empowerment initiatives is where we find success in our business.

[Ryan Napierski, CEO, President & Director at Nu Skin Enterprises]

So that's what we're acutely focused on. We'll look forward to updating you in coming quarters. And so please, please join the calls and and reach out with any questions. Thank you.

[Operator]

Thank you for your participation in today's conference. This does conclude the program, and you may now disconnect.

Participants

Executives

• B.G. Hunt, VP - Treasurer, IR & Admin Services
• Ryan Napierski, CEO, President & Director
• James Thomas, EVP & CFO

Analysts

• Dave Storms, Director - Equity Research at Stonegate Capital Partners